|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SERPINA5 |
Gene summary for SERPINA5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SERPINA5 | Gene ID | 5104 |
| Gene name | serpin family A member 5 | |
| Gene Alias | PAI-3 | |
| Cytomap | 14q32.13 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A024R6N9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5104 | SERPINA5 | S43 | Human | Liver | Cirrhotic | 1.08e-18 | 1.12e-01 | -0.0187 |
| 5104 | SERPINA5 | HCC1_Meng | Human | Liver | HCC | 5.03e-94 | -1.98e-01 | 0.0246 |
| 5104 | SERPINA5 | HCC2_Meng | Human | Liver | HCC | 8.14e-31 | -3.71e-01 | 0.0107 |
| 5104 | SERPINA5 | cirrhotic1 | Human | Liver | Cirrhotic | 8.09e-13 | 1.97e-01 | 0.0202 |
| 5104 | SERPINA5 | cirrhotic2 | Human | Liver | Cirrhotic | 7.95e-25 | 4.14e-01 | 0.0201 |
| 5104 | SERPINA5 | cirrhotic3 | Human | Liver | Cirrhotic | 1.65e-02 | -4.58e-02 | 0.0215 |
| 5104 | SERPINA5 | p6 | Human | Liver | Cyst | 1.10e-04 | -6.32e-01 | -0.0218 |
| 5104 | SERPINA5 | HCC1 | Human | Liver | HCC | 4.54e-02 | 2.96e+00 | 0.5336 |
| 5104 | SERPINA5 | HCC2 | Human | Liver | HCC | 3.83e-11 | 3.27e+00 | 0.5341 |
| 5104 | SERPINA5 | HCC5 | Human | Liver | HCC | 8.14e-14 | -6.32e-01 | 0.4932 |
| 5104 | SERPINA5 | Pt13.a | Human | Liver | HCC | 9.85e-07 | -4.51e-01 | 0.021 |
| 5104 | SERPINA5 | Pt13.b | Human | Liver | HCC | 1.04e-14 | -3.78e-01 | 0.0251 |
| 5104 | SERPINA5 | Pt13.c | Human | Liver | HCC | 1.07e-05 | -4.62e-01 | 0.0076 |
| 5104 | SERPINA5 | Pt14.b | Human | Liver | HCC | 3.05e-02 | -2.36e-01 | 0.018 |
| 5104 | SERPINA5 | Pt14.c | Human | Liver | HCC | 1.04e-03 | -5.75e-01 | 0.0054 |
| 5104 | SERPINA5 | Pt14.d | Human | Liver | HCC | 1.59e-02 | -3.53e-01 | 0.0143 |
| 5104 | SERPINA5 | S016 | Human | Liver | HCC | 2.88e-05 | -4.12e-01 | 0.2243 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005254712 | Liver | Cirrhotic | regulation of peptidase activity | 185/4634 | 461/18723 | 1.32e-13 | 1.09e-11 | 185 |
| GO:005254812 | Liver | Cirrhotic | regulation of endopeptidase activity | 172/4634 | 432/18723 | 2.12e-12 | 1.58e-10 | 172 |
| GO:004586112 | Liver | Cirrhotic | negative regulation of proteolysis | 136/4634 | 351/18723 | 3.46e-09 | 1.42e-07 | 136 |
| GO:005134612 | Liver | Cirrhotic | negative regulation of hydrolase activity | 139/4634 | 379/18723 | 1.24e-07 | 3.42e-06 | 139 |
| GO:004873212 | Liver | Cirrhotic | gland development | 154/4634 | 436/18723 | 4.03e-07 | 9.42e-06 | 154 |
| GO:001095111 | Liver | Cirrhotic | negative regulation of endopeptidase activity | 98/4634 | 252/18723 | 4.19e-07 | 9.77e-06 | 98 |
| GO:001046612 | Liver | Cirrhotic | negative regulation of peptidase activity | 100/4634 | 262/18723 | 8.90e-07 | 1.84e-05 | 100 |
| GO:001087611 | Liver | Cirrhotic | lipid localization | 147/4634 | 448/18723 | 6.24e-05 | 7.12e-04 | 147 |
| GO:000686911 | Liver | Cirrhotic | lipid transport | 128/4634 | 398/18723 | 4.54e-04 | 3.69e-03 | 128 |
| GO:00614585 | Liver | Cirrhotic | reproductive system development | 132/4634 | 427/18723 | 2.07e-03 | 1.28e-02 | 132 |
| GO:00486085 | Liver | Cirrhotic | reproductive structure development | 131/4634 | 424/18723 | 2.19e-03 | 1.34e-02 | 131 |
| GO:004873222 | Liver | HCC | gland development | 242/7958 | 436/18723 | 2.26e-08 | 5.28e-07 | 242 |
| GO:005254722 | Liver | HCC | regulation of peptidase activity | 247/7958 | 461/18723 | 8.28e-07 | 1.27e-05 | 247 |
| GO:005254822 | Liver | HCC | regulation of endopeptidase activity | 230/7958 | 432/18723 | 3.58e-06 | 4.68e-05 | 230 |
| GO:004586122 | Liver | HCC | negative regulation of proteolysis | 186/7958 | 351/18723 | 4.19e-05 | 4.11e-04 | 186 |
| GO:001087621 | Liver | HCC | lipid localization | 228/7958 | 448/18723 | 1.80e-04 | 1.41e-03 | 228 |
| GO:005134622 | Liver | HCC | negative regulation of hydrolase activity | 195/7958 | 379/18723 | 2.44e-04 | 1.82e-03 | 195 |
| GO:000686921 | Liver | HCC | lipid transport | 198/7958 | 398/18723 | 1.92e-03 | 9.78e-03 | 198 |
| GO:0061025 | Liver | HCC | membrane fusion | 88/7958 | 163/18723 | 1.98e-03 | 1.00e-02 | 88 |
| GO:001095121 | Liver | HCC | negative regulation of endopeptidase activity | 129/7958 | 252/18723 | 3.17e-03 | 1.47e-02 | 129 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
| hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
| hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
| hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SERPINA5 | SNV | Missense_Mutation | c.216N>G | p.Ile72Met | p.I72M | P05154 | protein_coding | deleterious(0) | probably_damaging(0.952) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| SERPINA5 | SNV | Missense_Mutation | c.1049N>T | p.Lys350Ile | p.K350I | P05154 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-BH-A0BS-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR | |
| SERPINA5 | SNV | Missense_Mutation | c.69N>A | p.His23Gln | p.H23Q | P05154 | protein_coding | tolerated(0.21) | benign(0.23) | TCGA-E2-A15O-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | PD | |
| SERPINA5 | SNV | Missense_Mutation | novel | c.263N>G | p.Lys88Arg | p.K88R | P05154 | protein_coding | tolerated(0.63) | benign(0.144) | TCGA-PE-A5DC-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| SERPINA5 | insertion | Nonsense_Mutation | novel | c.867_868insCACTCCTTGTAAGCATTCCTGCTCGCCTCTGCAGCTCC | p.Trp290HisfsTer4 | p.W290Hfs*4 | P05154 | protein_coding | TCGA-A8-A0A1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| SERPINA5 | SNV | Missense_Mutation | c.100N>A | p.Leu34Ile | p.L34I | P05154 | protein_coding | tolerated(0.36) | benign(0.015) | TCGA-MA-AA3X-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR | |
| SERPINA5 | SNV | Missense_Mutation | c.81N>T | p.Met27Ile | p.M27I | P05154 | protein_coding | tolerated(0.19) | benign(0) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| SERPINA5 | SNV | Missense_Mutation | c.826C>A | p.Gln276Lys | p.Q276K | P05154 | protein_coding | tolerated(0.55) | benign(0.014) | TCGA-AA-3866-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SERPINA5 | SNV | Missense_Mutation | novel | c.811A>G | p.Ser271Gly | p.S271G | P05154 | protein_coding | tolerated(0.29) | benign(0) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| SERPINA5 | SNV | Missense_Mutation | c.198N>A | p.Phe66Leu | p.F66L | P05154 | protein_coding | deleterious(0.03) | benign(0.012) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 5104 | SERPINA5 | PROTEASE INHIBITOR, ENZYME, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | gemcitabine | GEMCITABINE | 31616045 | |
| 5104 | SERPINA5 | PROTEASE INHIBITOR, ENZYME, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | THROMBIN | THROMBIN | 8136018 | |
| 5104 | SERPINA5 | PROTEASE INHIBITOR, ENZYME, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | HEPARIN | HEPARIN | 8136018 | |
| 5104 | SERPINA5 | PROTEASE INHIBITOR, ENZYME, DRUGGABLE GENOME, EXTERNAL SIDE OF PLASMA MEMBRANE | carboplatin | CARBOPLATIN | 31616045 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |